tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us
Genmab A/S (GMAB)
NASDAQ:GMAB
GMAB
Genmab
Stock Analysis
Analyst Forecasts
Technical Analysis
Options
Chart
Earnings
Dividends
Ownership
Financials
News & Insights
Similar Stocks
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports
Holding GMAB?
Track your performance easily
Link Broker

Genmab (GMAB) Stock News & Sentiment

510 Followers
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
Premium
Press Releases
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
5d ago
GMAB
Genmab Announces Strategic Financial Updates
Premium
Company Announcements
Genmab Announces Strategic Financial Updates
8d ago
6K
GMAB
Genmab Announces Share Capital Boost from Warrants
Premium
Company Announcements
Genmab Announces Share Capital Boost from Warrants
9d ago
6K
GMAB
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Premium
Press Releases
Capital Increase in Genmab as a Result of Employee Warrant Exercise
9d ago
GMAB
Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
Premium
Press Releases
Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
24d ago
GMAB
Genmab’s TEPKINLY Gains EU Approval for Lymphoma
Premium
Company Announcements
Genmab’s TEPKINLY Gains EU Approval for Lymphoma
30d ago
6K
GMAB
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
Premium
Press Releases
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
1M ago
GMAB
More GMAB News >

GMAB News on the Web

Investigational Rinatabart Sesutecan Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
Yahoo Finance
Neutral
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Yahoo Finance
Neutral
AbbVie Stock Up Almost 20% in 3 Months: Buy, Sell or Hold?
Zacks
Neutral
Top High Growth Tech Stocks To Watch In August 2024
Yahoo Finance
Neutral
3 Stocks Benefiting From the Aging Population
StockNews
Neutral
Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
Yahoo Finance
Neutral
3 Healthcare Stocks Positioned for Major Gains in 2024
StockNews
Neutral
AbbVie (ABBV) Gets Nod in EU for Lymphoma Drug's Expanded Use
Zacks
Neutral

News Score - Last 7 Days

Neutral
GMAB
Sector Average
Media Buzz
This Week1 articles
Weekly Average1.5 articles
News Sentiment
This Week50%
Sector Average60%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is GMAB’s Media Buzz Sentiment?
1 articles about GMAB were published this week. In an average week, 1.5 articles are published.
    What is GMAB’s weekly average amount of articles?
    In an average week, 1.5 articles about GMAB are published.
      What is GMAB’s News Sentiment?
      50% of articles about GMAB were positive this week, compared to its sector average of 60%.
        Healthcare Stocks that are Trending in the News
        NUVLNuvalent
        BLCOBausch + Lomb Corporation
        INCYIncyte
        ACRVAcrivon Therapeutics, Inc.
        EWTXEdgewise Therapeutics
        Showing the stocks with the most bullish news sentiment over the past week

        Become an Expert with TipRanks Premium

        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis
        Subscribe NowSee Plans & Pricing